Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
75pct
34d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the Subcommittee on the Constitution and Civil Justice.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Bipartisan Healthcare Stabilization Act (Alexander-Murray) Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation S. 2554, Patient Right to Know Drug Prices Act
Client expense: $320,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
H.R. 246 - Jobs and Premium Protection Act. ACA Implementation, Medicare Advantage, Prescription Drugs. S. 1859 - Healthcare Tax Relief Act. S. 1978 - Small Business and Family Health Tax Relief Act of 2017. H.R. 4620 - Protecting Families and Small Businesses Act of 2017. Request for Information 0991-ZA49, HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. H.R. 6 - SUPPORT for Patients and Communities Act. S. 3120 - HEAL Act of 2018. S. 2554 - Patient Right to Know Drug Prices Act. H.R. 878; H.R. 2368/S. 204 - Right-to-Try Legislation.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Bipartisan Healthcare Stabilization Act (Alexander-Murray) Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation S. 2554, Patient Right to Know Drug Prices Act
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
H.R. 246 - Jobs and Premium Protection Act. ACA Implementation, Medicare Advantage, Prescription Drugs. S. 1859 - Healthcare Tax Relief Act. S. 1978 - Small Business and Family Health Tax Relief Act of 2017. H.R. 4620 - Protecting Families and Small Businesses Act of 2017. Request for Information 0991-ZA49, HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. H.R. 6 - SUPPORT for Patients and Communities Act. S. 3120 - HEAL Act of 2018. S. 2554 - Patient Right to Know Drug Prices Act. H.R. 878; H.R. 2368/S. 204 - Right-to-Try Legislation.
Client expense: Not reported · Firm income: $80,000
2018 · second_quarter · Pharmacy
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Client expense: $540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Client expense: $540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Monitored issues related to H.R. 2368 and H.R. 878, The Right to Try Act of 2017 and S. 204 and H.R. 5247, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Issues related to opioids and prescription drug monitoring programs including H.R. 5812, the CONNECTIONS Act.
Client expense: Not reported · Firm income: $63,750
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2018 · second_quarter · Health Issues
Bipartisan Healthcare Stabilization Act (Alexander-Murray) Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation Request for Information 0991-ZA49, HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2018 · second_quarter · Health Issues
Issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
CMS Manual - Reimbursement coding HR 5812 Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act of 2018 HR 2368 Right to Try Act HR 5247 - Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 S 204 Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 HR 878 Right to Try Act of 2017
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Issues related to lung disease treatment, prevention and research; public health; Issues related asthma; COPD; influenza; lung cancer; pneumonia; tuberculosis and other lung diseases; Issues related to tobacco cessation; Issues related to the Affordable Care Act; Issues related to the Childrens Health Insurance Program; Issues related to the President's Budget; Issues related to FY 2019 Appropriations;H.J.RES.123, Making further continuing appropriations for fiscal year 2018, and for other purposes; H.R.878, Right to Try Act of 2017; H.R.1121, Pre-existing Conditions Protection Act of 2017; H.R.1625, Consolidated Appropriations Act, 2018; H.R.2368, Right to Try Act; H.R.2550, Medicare Telehealth Parity Act of 2017; H.R.2810, National Defense Authorization Act for Fiscal Year 2018; H.R.3258, Marketplace Certainty Act; H.R.3267, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2018; H.R.3358, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; H.R.3362, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2018; H.R.4667, Making further supplemental appropriations for the fiscal year ending September 30, 2018, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes.; H.R.4695, Bipartisan Market Stabilization and Innovation Act of 2017; H.R.4897, Women and Lung Cancer Research and Preventive Services Act of 2018; H.RES.827, Expressing support for the designation of April 2018 as "National Donate Life Month".; S.204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017; S.974, CREATES Act of 2017; S.1462, Marketplace Certainty Act; S.1519, National Defense Authorization Act for Fiscal Year 2018; S.1557, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2018; S.1662, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2018; S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018; S.1780, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2018; S. 1835, Lower Premiums Through Reinsurance Act of 2017; S.2494, Fair Care Act; S.2507, Improving Choices in Health Care Coverage Act; S.RES.152, A resolution expressing support for the designation of April 2017 as "National Donate Life Month".;  
2018 · first_quarter · Health Issues
Bipartisan Healthcare Stabilization Act (Alexander-Murray) Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2018 · first_quarter · Health Issues
Monitored issues related to H.R. 2368 and H.R. 878, The Right to Try Act of 2017 and S. 204 and H.R. 5247, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Monitored issues related to opioids and prescription drug monitoring programs.
Client expense: Not reported · Firm income: $63,750
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2018 · first_quarter · Health Issues
Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Health Issues
Monitored issues related to Right to Try including H.R. 2368 and H.R. 878, Right to Try Act of 2017, and S. 204 and H.R. 5247, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; S. 1827, The Keep Kids' Insurance Dependable and Secure Act of 2017, H.R. 3921, HEALTHY KIDS Act and issues related to prescription drugs.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · first_quarter · Pharmacy
ADHD Awareness *Drug Values -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Newborn Screening
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
H.R. 394, Restoring Access to Medication Act of 2017, all provisions S. 85, Restoring Access to Medication Act of 2017, all provisions H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to Fix NICS Act, Dickey Amendment H.R. 3545, Overdose Prevention and Patient Safety Act, all provisions H.R. 5009, Jessie's Law, all provisions H.R. 5311, Comprehensive Addiction and Recovery Act (CARA) 2.0 Act of 2018, all provisions S. 2456, Comprehensive Addiction and Recovery Act (CARA) 2.0 Act of 2018, all provisions H.R. 1375, Prescriber Support Act of 2017, all provisions S. 2135, Fix NICS Act of 2017, all provisions H.R. 4909, Student, Teachers, and Officers Preventing (STOP) School Violence Act of 2018, all provisions H.R. 5002, Advancing Cutting-Edge (ACE) Research Act, all provisions S. 2406, Advancing Cutting-Edge (ACE) Research Act, all provisions H.R. 878, Right to Try Act of 2017, all provisions H.R. 2368, Right to Try Act, all provisions H.R. 5247, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018, all provisions S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, all provisions H.R. 4191, HHS Cybersecurity Modernization Act, all provisions H.R. 4163, Cyber Shield Act of 2017, all provisions S. 2020, Cyber Shield Act of 2017, all provisions H.R. 4613, Ensuring Patient Access to Healthcare Records Act of 2017 H.R. 2063, Opioid Preventing Abuse through Continuing Education (Opioid PACE) Act of 2017, all provisions S. 1803, Marijuana Effective Drug Studies Act of 2017, all provisions H.R. 1318, Preventing Maternal Deaths Act of 2017, all provisions S. 1112, Maternal Health Accountability Act of 2017, all provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017 H.R. 5219, Opioid Prescription Verification Act of 2018, all provisions 42 CFR/Privacy of substance abuse records Opioid Abuse Cost-sharing reduction payments and ACA stabilization Health Savings Accounts - Prescription requirement for over-the-counter medications Telemedicine Electronic Health Records (EHR) Electronic prescribing of controlled substances Prescription Drug Monitoring Programs (PDMPs) Interoperability of EHRs and PDMPs Prior authorization and medically assisted therapy Continuing Medical Education (CME) requirements for DEA licensure Gun Violence Prescription drug pricing/transparency/value/prior authorization burdens Provider Price Transparency Continuing Medical Education (CME) and opioid/pain management prescribing Cybersecurity Laboratory Developed Tests (LDTs) Conscience Rights/Delegation of Authority Title X Funding Regulatory burdens FDA oversight of digital health tools/modernization options In-office Drug Compounding Virtual Diabetes Prevention Program/Telehealth Blood pressure device validation/accuracy
2018 · first_quarter · Health Issues
H.R. 2368, Right to Try Act. H.R. 878, Right to Try Act of 2017. H.R. 5247/ S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Issues regarding access to care for those with rare diseases.
Client expense: Not reported · Firm income: $52,500
Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
2017 · third_quarter · Pharmacy
ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding, including expansion for rare diseases -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703) -Newborn Screening -Study eligibilities for DOD PRMRP
Client expense: $550,000 · Firm income: Not reported
2017 · fourth_quarter · Health Issues
Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored issues concerning value based contracting.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · fourth_quarter · Health Issues
H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Issues regarding access to care for those with rare diseases.
Client expense: Not reported · Firm income: $52,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Health Issues
Bipartisan Healthcare Stabilization Act (Alexander-Murray) Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation H.R. 2026, Pharmaceutical Information Exchange Act
Client expense: $430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2017 · fourth_quarter · Health Issues
Monitored issues related to H.R. 2368 and H.R. 878 related to The Right to Try and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017. Monitored issues related to the drug supply chain.
Client expense: Not reported · Firm income: $63,750
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2017 · fourth_quarter · Pharmacy
ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding, including expansion for rare diseases -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703) -Newborn Screening -Study eligibilities for DOD PRMRP
Client expense: $710,000 · Firm income: Not reported
2017 · fourth_quarter · Health Issues
Issues related to antimicrobials; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
H.R. 246, Jobs and Premium Protection Act H.R. 1628, American Health Care Act; Senate Amendment - Better Care Reconciliation Act Affordable Care Act Implementation H.R. 2026 Pharmaceutical Information Exchange Act H.R. 878, H.R. 2368, S. 204 Right-to-Try Legislation H.R. 2026, Pharmaceutical Information Exchange Act
Client expense: $320,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2017 · third_quarter · Pharmacy
ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding, including expansion for rare diseases -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703) -Newborn Screening -Study eligibilities for DOD PRMRP
Client expense: $550,000 · Firm income: Not reported
2017 · second_quarter · Health Issues
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Client expense: $740,000 · Firm income: Not reported
2017 · second_quarter · Pharmacy
ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan drug tax credit -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Trickett Wendler Right to Try Act of 2017 (S.204) and Right to Try Act (H.R. 878 and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703)
Client expense: $580,000 · Firm income: Not reported
| Republican |
| PA |
| Mark Sanford | Republican | SC |
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $260,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Veterans Affairs, Dept of (VA), White House Office
Client expense: $6,590,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE